Sunshine Biopharma Inc. Warrant
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor … Read more
Sunshine Biopharma Inc. Warrant (SBFMW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.030x
Based on the latest financial reports, Sunshine Biopharma Inc. Warrant (SBFMW) has a cash flow conversion efficiency ratio of -0.030x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-727.80K) by net assets ($24.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sunshine Biopharma Inc. Warrant - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Sunshine Biopharma Inc. Warrant's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sunshine Biopharma Inc. Warrant Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunshine Biopharma Inc. Warrant ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WORTHINGTON IND
BE:WTH
|
0.046x |
|
Right On Brands Inc
PINK:RTON
|
-0.339x |
|
SAB Finance as
PR:SABFG
|
N/A |
|
EvokAI Creative Labs Inc
OTCQB:OKAIF
|
0.089x |
|
VIASAT - Dusseldorf Stock Exchang
DU:VS1
|
0.030x |
|
ELCORA ADVANCED MAT.CORP.
F:ELM
|
N/A |
|
Wang & Lee Group, Inc. Ordinary Shares
NASDAQ:WLGS
|
0.051x |
|
Clinomics Inc
KQ:352770
|
-0.238x |
Annual Cash Flow Conversion Efficiency for Sunshine Biopharma Inc. Warrant (2007–2024)
The table below shows the annual cash flow conversion efficiency of Sunshine Biopharma Inc. Warrant from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $23.50 Million | $-12.53 Million | -0.533x | -28.87% |
| 2023-12-31 | $21.21 Million | $-8.78 Million | -0.414x | -70.51% |
| 2022-12-31 | $21.63 Million | $-5.25 Million | -0.243x | +97.19% |
| 2021-12-31 | $211.66K | $-1.83 Million | -8.642x | -1355.36% |
| 2020-12-31 | $-954.84K | $-657.30K | 0.688x | +2.10% |
| 2019-12-31 | $-735.38K | $-495.80K | 0.674x | -92.67% |
| 2018-12-31 | $-55.75K | $-512.81K | 9.198x | +870.28% |
| 2017-12-31 | $-573.36K | $-543.52K | 0.948x | -36.73% |
| 2016-12-31 | $-209.70K | $-314.18K | 1.498x | +3.10% |
| 2015-12-31 | $-597.04K | $-867.64K | 1.453x | +4.58% |
| 2014-12-31 | $-387.58K | $-538.60K | 1.390x | -98.10% |
| 2013-12-31 | $-7.71K | $-564.40K | 73.203x | +1411.63% |
| 2012-12-31 | $70.43K | $-393.05K | -5.581x | -93.36% |
| 2011-12-31 | $103.00K | $-297.30K | -2.886x | -62.59% |
| 2010-12-31 | $196.22K | $-348.32K | -1.775x | -1597.95% |
| 2009-12-31 | $97.80K | $-10.22K | -0.105x | -106.72% |
| 2008-12-31 | $-17.71K | $-27.53K | 1.555x | +767.03% |
| 2007-12-31 | $13.39K | $-3.12K | -0.233x | -- |